Recent News

• 09.12.2025 - Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
• 09.12.2025 - Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
• 09.12.2025 - PBGENE-HBV Chronic Hepatitis B Program
• 09.08.2025 - Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
• 09.08.2025 - Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
• 08.07.2025 - Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
• 08.07.2025 - Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
• 08.06.2025 - Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
• 08.06.2025 - Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
• 08.04.2025 - Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Recent Filings

• 09.02.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.06.2025 - 8-K Current report
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors